☆ 4.7 Meeting Abstract

HER2CLIMB-04: Phase 2 open label trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+unresectable locally advanced or metastatic breast cancer with and without brain metastases (trial in progress).

JOURNAL OF CLINICAL ONCOLOGY (2021)

Rate this paper

The primary rating indicates the level of overall quality for the paper. Secondary ratings independently reflect strengths or weaknesses of the paper.

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Become a Peeref-certified reviewer

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started

HER2CLIMB-04: Phase 2 open label trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+unresectable locally advanced or metastatic breast cancer with and without brain metastases (trial in progress).

Rate this paper

Find Funding. Review Successful Grants.

Become a Peeref-certified reviewer

Export Citation

Share Paper